MTRAC Commissioning Support: Denosumab (Prolia®) for the treatment of osteoporosis in postmenopausal women -

MTRAC Commissioning Support: Denosumab (Prolia®) for the treatment of osteoporosis in postmenopausal women
Information type: Evidence summaries
Source: Midlands Therapeutics Review and Advisory Committee
Specialities: Musculo-skeletal disorders
Summary
MTRAC have reviewed denosumab for the treatment of osteoporosis in postmenopausal women. They consider it to be suitable for prescribing in primary care following secondary care initiation and stabilisation, but list a number of considerations for commissioners.
UKMi comment
MTRAC have published a template for effective shared care agreement for denosumab alongside this commissioning support – this is available via the link below.
Related links: Effective shared care agreement template